Galectin Therapeutics Inc... (GALT)
NASDAQ: GALT
· Real-Time Price · USD
3.57
-0.19 (-5.05%)
At close: Aug 15, 2025, 3:59 PM
3.55
-0.56%
After-hours: Aug 15, 2025, 06:50 PM EDT
Galectin Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | 80K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 10K | n/a | 9K | 9K | 9K | 8K | n/a | n/a | 8K | n/a | 7K | 10K | 11K | 10K | 10K | 10K |
Gross Profit | n/a | n/a | n/a | -9K | -9K | 71K | -8K | n/a | n/a | -8K | n/a | -7K | -10K | -11K | -10K | -10K | -10K |
Operating Income | n/a | -12.43M | -9.07M | -11.29M | -9.65M | -9.56M | -9.17M | -9M | -10.34M | -10.63M | -8.12M | -9.66M | -9.94M | -7.42M | -8.24M | -8.19M | -6.32M |
Interest Income | 35K | 84K | 93K | 80K | 80K | 74K | 62K | 50K | 44K | 30K | 18K | 3K | 1K | n/a | 1K | 1K | 1K |
Pretax Income | -9.63M | -11.97M | -11.22M | -12.37M | -11.49M | -10M | -10.43M | -9.11M | -11.53M | -10.63M | -8.6M | -9.61M | -9.93M | -7.22M | -8.52M | -8.45M | -6.34M |
Net Income | -9.63M | -11.97M | -11.22M | -12.37M | -11.49M | -10M | -10.43M | -9.11M | -11.53M | -10.63M | -8.6M | -9.61M | -9.93M | -7.22M | -8.52M | -8.45M | -6.34M |
Selling & General & Admin | 1.41M | 1.32M | 1.47M | 1.48M | 1.59M | 1.33M | 1.43M | 1.63M | 1.54M | 1.63M | 1.52M | 1.59M | 1.88M | 1.57M | 1.63M | 1.74M | 1.42M |
Research & Development | 6.49M | 11.11M | 7.59M | 9.81M | 8.05M | 8.23M | 7.73M | 7.37M | 8.8M | 9.01M | 6.6M | 8.07M | 8.06M | 5.86M | 6.61M | 6.45M | 4.9M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 7.9M | 12.43M | 9.07M | 11.29M | 9.65M | 9.56M | 9.17M | 9M | 10.34M | 10.63M | 8.12M | 9.66M | 9.94M | 7.42M | 8.24M | 8.19M | 6.32M |
Interest Expense | 1.74M | 1.73M | 1.49M | 1.27M | 1.05M | 847K | 835K | 650K | 460K | 308K | 269K | 229K | 227K | 272K | 111K | 85K | 22K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 12.43M | 9.07M | 11.29M | 9.65M | 9.56M | 9.17M | 9M | 10.34M | 10.63M | 8.12M | 9.66M | 9.94M | 7.42M | 8.24M | 8.19M | 6.32M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 63.2M | 62.74M | 62.28M | 62.23M | 61.98M | 60.16M | 59.7M | 59.58M | 59.48M | 59.43M | 59.4M | 59.39M | 59.35M | 58.53M | 59.29M | 58.31M | 57.13M |
Shares Outstanding (Diluted) | 63.2M | 62.74M | 62.28M | 62.23M | 61.98M | 60.16M | 59.7M | 59.58M | 59.48M | 59.43M | 59.4M | 59.39M | 59.35M | 58.53M | 59.29M | 58.31M | 57.13M |
EPS (Basic) | -0.15 | -0.19 | -0.18 | -0.2 | -0.19 | -0.16 | -0.24 | -0.15 | -0.19 | -0.51 | -0.14 | -0.16 | -0.17 | -0.12 | -0.14 | -0.15 | -0.11 |
EPS (Diluted) | -0.15 | -0.19 | -0.18 | -0.2 | -0.19 | -0.16 | -0.24 | -0.15 | -0.19 | -0.51 | -0.14 | -0.16 | -0.17 | -0.12 | -0.14 | -0.15 | -0.11 |
EBITDA | n/a | -10.23M | -9.72M | -11.09M | -10.43M | -9.14M | -9.59M | -8.46M | -11.04M | -10.32M | -8.32M | -9.38M | -9.7M | -6.94M | -8.4M | -8.35M | -6.31M |
EBIT | n/a | -10.24M | -9.73M | -11.1M | -10.44M | -9.15M | -9.59M | -8.46M | -11.07M | -10.33M | -8.33M | -9.38M | -9.71M | -6.95M | -8.41M | -8.36M | -6.32M |
Depreciation & Amortization | n/a | 10K | 9K | 9K | 9K | 9K | 8K | n/a | 32K | 8K | 7K | 7K | 10K | 11K | 10K | 10K | 10K |